Thursday 16 October, 2025
Objectives: Morphine is the most commonly used opioid to alleviate moderate-severe pain [1]. For patients with gastrointestinal pain, rectal administration…
Read morePoster: Drug/Disease modeling - CNS
A model for the respiratory effects of remifentanil and propofol during sedation and analgesia
Thursday 16 October, 2025
Objectives: Propofol and remifentanil are commonly combined for sedation and may act synergistically on the respiratory system. Most models describing…
Read moreDifferences in response to scopolamine between young and elderly healthy adults using a modelling approach: reduction in the central cholinergic system in the elderly?
Thursday 16 October, 2025
Objectives: Scopolamine is a non-selective, muscarinic receptor antagonist that is used in a cholinergic challenge test for cognitive impairment. The test…
Read moreOptimal dosing recommendations for combination therapy in epilepsy
Thursday 16 October, 2025
Objectives: Despite numerous publications showing evidence of pharmacokinetic interaction between antiepileptic drugs (AED), this information has not been used to support…
Read moreA PKPD Hidden Markov Model for Lamotrigine in all age groups
Thursday 16 October, 2025
Objectives: Due to high variability in pharmacokinetics, pharmacodynamics, disease progression and maturation, clear dosing recommendations regarding anti-epileptic drugs are often not…
Read moreDifferentiation between Parkinson’s and Parkinson’s-like patients in MDS-UPDRS-based diagnosis
Thursday 16 October, 2025
Objectives: It has been shown in the PPMI study [1] that approximately 15% of patients with MDS-UPDRS scores suggesting Parkinson’s disease…
Read moreExposure-Response Analysis of Peginterferon Beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis
Thursday 16 October, 2025
Objectives: To establish a population pharmacokinetic (PK) model of peginterferon beta-1a (PEG-IFN) in relapsing remitting multiple sclerosis (RRMS) patients and develop…
Read moreExposure-Response Analysis of Peginterferon beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis
Thursday 16 October, 2025
Objectives: To establish a population pharmacokinetic (PK) model of peginterferon beta-1a (PEGIFN) in relapsing remitting multiple sclerosis (RRMS) patients and…
Read moreOptimal phase 2 dose selection based on the relationship between exposure and target occupancy
Thursday 16 October, 2025
Objectives: Target occupancy is a useful metric to confirm drug engagement with the target in early clinical phase and to…
Read moreModeling the effect of interferon beta-1b on contrast enhancing lesions in relapsing-remitting multiple sclerosis
Thursday 16 October, 2025
Background: Multiple sclerosis (MS) is a chronic autoimmune disease that may affect both white matter and gray matter [1-3]. The…
Read more